ArticleScientific reports2026
Rational design and antibacterial assessment of novel pyranopyrazole derivatives: a combined experimental and in silico study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pyranopyrazole derivatives were synthesized via multicomponent reactions and characterized using spectroscopic techniques including IR, 1H-NMR, 13C-NMR, and mass spectrometry. In vitro antibacterial evaluation revealed that compounds 2b, 3a, 5b, and 7b exhibited significant activity against Gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis), while compounds 4b, 4d, 6b, and 8b demonstrated potent activity against Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli). Quantum chemical calculations at the DFT/B3LYP/6-31G(d,p) level revealed HOMO–LUMO energy gaps ranging from 4.50 to 5.38 eV, with lower energy gaps correlating with enhanced antibacterial activity. Molecular electrostatic potential (MEP) analysis identified key electron-rich and electron-deficient regions responsible for target recognition. In silico molecular docking studies against tyrosyl-tRNA synthetase, an essential bacterial enzyme, demonstrated strong binding affinities with binding energies ranging from −7.84 to −11.30 kcal/mol and calculated inhibition constants (Ki) of 5.23 to 1790 nM. Key interactions involved hydrogen bonding and π-π stacking with active site residues Tyr34, His48, Asp177, and Gln196. ADME property predictions indicated favorable drug-like characteristics with compliance to Lipinski’s Rule of Five and high gastrointestinal absorption. These outstanding results could be due to the presence of aromatic moiety, halogen atom and cyano-group which enhance lipophilicity and membrane permeability in addition to the synergistic effect of both pyran and pyrazole nucleus. These integrated findings establish pyranopyrazoles as promising scaffolds for antibacterial drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.